Tags Pharma

In silico target identification & rare diseases: case study

Discover how Kantify and I-Stem have combine artificial intelligence and phenotypic assays to perform unbiased target identification in a short timeframe

AI in drug discovery: ADMET property prediction

Discover how artificial intelligence can help you select lead compounds that are both to be effective and do not have adverse effects on patients

Advancing Drug Discovery with Artificial Intelligence

Discover how to enhance your drug discovery pipeline using our novel Artificial Intelligence technology

Tue 23 Aug 2022

Using Zeptomics for hit discovery

Learn more about the performance of ZeptoHit, the hit prediction algorithm of Zeptomics

Wed 11 May 2022

A new AI/ML approach for ligand identification

Only 1% of compound to protein interactions are currently known. We are on a mission to predict the remaining 99%.

Fri 19 Mar 2021

ZeptoNet White Paper: AI for drug discovery

We present ZeptoNet, our novel machine learning technology for in silico small molecule screening at scale

Mon 17 Oct 2022

Kantify & Mcule harness data to accelerate drug discovery

Kantify, using its AI technology for drug discovery and Mcule,with its compound sourcing platform, are collaborating to leverage data for better hit prediction

Wed 20 Jul 2022

Fragile X Syndrome: Innovative Approaches to Finding a Cure

Join the talk of our CTO at this cornerstone online event of the Fragile-X patient and research communityt

Mon 30 May 2022

Targeted Protein Degradation : Kantify at Proteocure event

Kantify spoke about the latest progress of AI/ML for Degraders at the event of Proteocure

Fri 19 Mar 2021

Kantify announces its new drug discovery technology

Kantify announces ZeptoNet, its new Virtual screening technology of small molecules

Tue 16 Mar 2021

Kantify at the Belgian AI Week 2021

Kantify is taking part in several events on Artificial Intelligence (AI) during the 2021 Belgian AI Week.